Newsletter July 2025
Panel Screening Opportunity in TNBC Models

Dear Colleagues,
we’re offering a unique opportunity to evaluate your compound across
a panel of 14 well-characterized triple-negative breast cancer
(TNBC) models. This joint screening initiative enables you to benefit
from shared controls, streamlined workflows, and competitive pricing —
all while generating robust, translatable efficacy data. Optional add-on
services such as IHC, PK/PD, and histology are also available to deepen
your insights. EPO’s expertise in TNBC modeling and drug evaluation was
recently featured in an oral presentation at AACR 2025 [Abstract] highlighting our leadership in translational oncology research.
Test the efficacy of your compound(s) in a panel of 14 TNBC PDX models
Enrollment is now open through August 15th
FEATURES
- Access to a curated panel of 14 well-characterized triple-negative breast cancer (TNBC) models, representing diverse molecular and phenotypic profiles.
- Each model is backed by RNA sequencing data, mutations and tissue bank samplesModels have been pre-tested with clinically relevant compounds
- Standardized 8-week study duration, with tumor growth inhibition as the primary efficacy read-out
- Competitive pricing available when selecting the full 14-model panel screen, leveraging shared controls and streamlined workflows for maximum value.
- Option to include additional services such as IHC, PK/PD, and histology and sampling (frozen, FFPE, blood) tailored to support deeper mechanistic insights and biomarker discovery
Please contact us directly to discuss your compound of interest, reserve your slot, or request a detailed study proposal.
Best regards,
Jens Hoffmann (CEO), Wolfgang Walther (CSO), Antje Wengner (CSO) EPO Berlin-Buch

Related Talks and Publications
Talk AACR, Chicago 2025
- Triple negative breast cancer (TNBC) PDX models for preclinical investigation of novel therapies
Hoffmann J, Behrens D
Abstract
Publications
- Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
Heynen GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, Alcaniz J, Montaudon E, Marangoni E, Birchmeier W. Breast
Cancer Res. 2022;24(1):23 (Weblink) - MiR-1287-5p inhibits triple negative breast cancer growth by
interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells
for PI3Kinase inhibitors.
Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M.
Breast Cancer Res. 2019;21(1):20 (Weblink)